Carmichael Hill & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Carmichael Hill & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-21	Closed	-$2.24K	–	790
2024 Q2	$2.24K	Hold	21	–	–	﹤0.01%	696
2024 Q1	$2.53K	Hold	21	–	–	﹤0.01%	676
2023 Q4	$2.58K	Hold	21	–	–	﹤0.01%	696
2023 Q3	$2.72K	Hold	21	–	–	﹤0.01%	681
2023 Q2	$2.6K	Hold	21	–	–	﹤0.01%	686
2023 Q1	$3.07K	Hold	21	–	–	﹤0.01%	671
2022 Q4	$3.35K	Hold	21	–	–	﹤0.01%	654
2022 Q3	$3K	Hold	21	–	–	﹤0.01%	716
2022 Q2	$3K	Hold	21	–	–	﹤0.01%	702
2022 Q1	$3K	Hold	21	–	–	﹤0.01%	727
2021 Q4	$3K	Hold	21	–	–	﹤0.01%	744
2021 Q3	$3K	Sell	21 -13	-38%	-$1.96K	﹤0.01%	727
2021 Q2	$6K	Buy	34 +3	+10%	+$520	﹤0.01%	655
2021 Q1	$5K	Hold	31	–	–	﹤0.01%	654
2020 Q4	$5K	Hold	31	–	–	﹤0.01%	627
2020 Q3	$4K	Hold	31	–	–	﹤0.01%	610
2020 Q2	$3K	Hold	31	–	–	﹤0.01%	604
2020 Q1	$3K	Hold	31	–	–	﹤0.01%	577
2019 Q4	$5K	Buy	+31	New	+$4.22K	﹤0.01%	556

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Carmichael Hill & Associates's JAZZ Position: Q3 2024 in Review

Carmichael Hill & Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2024, closing a stake of 21 shares — an estimated $2.24K sold.

Carmichael Hill & Associates first reported a position in JAZZ in Q4 2019 and held it in 19 quarters. The position peaked at $6K in Q2 2021. 477 funds tracked by Wall St. Rank hold JAZZ as of Q3 2024.

Carmichael Hill & Associates reported no remaining Jazz Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Carmichael Hill & Associates sold 21 Jazz Pharmaceuticals shares in Q3 2024, an estimated $2.24K.
Carmichael Hill & Associates first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 19 quarters.
Carmichael Hill & Associates's Jazz Pharmaceuticals position peaked at $6K in Q2 2021.
477 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.